Exploiting NK cells for suppression of unwanted immune responses in transplantation

Project 20

Project leaders:

MD / PhD Chiara Romagnani

Deutsches Rheuma-Forschungszentrum

Postal address:

Charitéplatz 1

10117 Berlin

t: +49 30 28460 681

f: +49 30 28460 612


Prof. Dr. med. Lutz Uharek

CharitéUniversitätsmedizin Berlin

CBF: Campus Benjamin Franklin

Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin

Postal address:

Hindenburgdamm 30

12203 Berlin

t: +49 30 8445 4550

f: +49 30 84454 021


In the previous funding period, we have exploited adoptive transfer of NK cells in the course of a Phase I/II clinical trial with the aim to control tumor relapse and prevent graft versus host disease (GvHD), which represent the most severe complication during allogeneic hematopoietic stem cell transplantation (HSCT) and identified a novel population of polyfunctional NK cells, combining high self renewal ability with potent effector functions. In the current application, we will exploit polyfunctional NK cells in combination or not with regulatory T cells to modulate GvHD and employ strategies to preserve and potentiate NK cell polyfunctionality. Altogether, our approach aims to implement clinical strategies devoted to achieve maximal graft versus leukemia and minimal GvHD during allogeneic HSCT.

Research Database

For more details please use the Charité undefinedresearch database.